stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Return on assets
Harmony Biosciences Holdings, Inc.'s return on assets over the twelve months to 30 September 2026 was 13.3%, down 0.7 percentage points from fiscal 2025 (14.0%). Over the past ten years it has ranged from −191.0% (fiscal 2019) to 32.8% (fiscal 2022); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.0% | (2.09) |
| FY2024 | 16.1% | (1.28) |
| FY2023 | 17.4% | (15.43) |
| FY2022 | 32.8% | 24.74 |
| FY2021 | 8.04% | 31.96 |
| FY2020 | −23.9% | 167.12 |
| FY2019 | −191.0% | (34.05) |
| FY2018 | −157.0% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | 13.3% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| FTRE Fortrea Holdings Inc. compare | −2.51% |
| SRPT Sarepta Therapeutics, Inc. compare | −3.44% |
| VIR Vir Biotechnology, Inc. compare | −17.3% |
| TRVI Trevi Therapeutics, Inc. compare | −19.0% |
| MAZE Maze Therapeutics, Inc. compare | −32.0% |
| REPL Replimune Group, Inc. compare | −71.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)